3G6 Stock Overview
Engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GNI Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥17.90 |
| 52 Week High | JP¥22.60 |
| 52 Week Low | JP¥9.75 |
| Beta | 1.38 |
| 11 Month Change | 3.47% |
| 3 Month Change | 79.00% |
| 1 Year Change | 43.20% |
| 33 Year Change | 52.99% |
| 5 Year Change | 23.45% |
| Change since IPO | 995.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3G6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.3% | -0.4% | -1.8% |
| 1Y | 43.2% | -15.4% | 13.6% |
Return vs Industry: 3G6 exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 3G6 exceeded the German Market which returned 13.6% over the past year.
Price Volatility
| 3G6 volatility | |
|---|---|
| 3G6 Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3G6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3G6's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 843 | Ying Luo | www.gnipharma.com |
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy.
GNI Group Ltd. Fundamentals Summary
| 3G6 fundamental statistics | |
|---|---|
| Market cap | €915.70m |
| Earnings (TTM) | €40.91m |
| Revenue (TTM) | €142.99m |
22.4x
P/E Ratio6.4x
P/S RatioIs 3G6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3G6 income statement (TTM) | |
|---|---|
| Revenue | JP¥23.65b |
| Cost of Revenue | JP¥4.41b |
| Gross Profit | JP¥19.24b |
| Other Expenses | JP¥12.48b |
| Earnings | JP¥6.77b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | 135.15 |
| Gross Margin | 81.37% |
| Net Profit Margin | 28.61% |
| Debt/Equity Ratio | 13.8% |
How did 3G6 perform over the long term?
See historical performance and comparison